Ciba-geigy Corporation

Henkel Kommanditgesellschaft Auf Aktien

Peter H Stahl

Pier G Ferrini

Beat Schmitz

Jonathan Green

Carlo Voellmy

Claudio Gamboni

Process for the preparation of an oral solid dosage form containing

The invention relates to topically administrable pharmaceutical preparations containing pharmaceutically acceptable methanediphosphonic acid derivatives of formula ##STR1## and their salts, wherein R.sub.1 and R.sub.2 are hydrogen or C.sub.1 -C.sub.3 alkyl.

Topical formulations

The invention relates to topically adminstrable pharmaceutical preparations containing pharmaceutically acceptable methanediphosphonic acid derivatives of formula ##STR1## and their salts, wherein each of R.sub.1 and R.sub.2 is halogen, or wherein R.sub.1 is hydrogen and R.sub.2 is Ar--S-- or Het.sub.1 --NH--, in which Ar is unsubstituted or substituted phenyl and Het.sub.1 is unsubstituted or substituted, monocyclic, 5- or 6-membered monoaza-, diaza- or thiaza-aryl that is bonded via a ring carbon atom, or wherein R.sub.1 is hydrogen or hydroxy and R.sub.2 is --A--R.sub.3, in which A is alkylene and, on the one hand, R.sub.3 is Het.sub.2, which is Het.sub.1 bonded via a ring carbon or ring nitrogen atom, or, on the other hand, R.sub.3 is hydrogen, or amino that is unsubsituted or mono- or di-substituted by identical or different substituents selected from alkyl, cycloalkyl, Ar-alkyl, Ar-O-alkyl, Ar-S-alkyl and Het.sub.1 -alkyl, or that is disubstituted by optionally Ar-containing alkylene, wherein two alkylene carbon atoms mar additionally be linked to one another via alkylene and Ar and Het.sub.1 are each as defined above, with the proviso that when R.sub.2 is --A--R.sub. 3, A is ethylene and R.sub.3 is unsubstituted or C.sub.1 -C.sub.3 alkyl-substituted amino, R.sub.1 is other than hydroxy.

Topically administrable pharmaceutical preparations

The invention relates to a novel crystal modification, containing water of crystallization, of disodium 3-amino-1-hydroxypropane-1,1-diphosphonate of the formula ##STR1## and to a process for the manufacture thereof. This modification is suitable for the oral treatment of disorders of the calcium and phosphate metabolism and associated diseases in warm-blooded animals.

Crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate

Preparation of crystalline disodium

Growing community of inventors

Freiburg, Germany

Peter H Stahl